Generic Oncology Drugs Market Report: Global Industry Trends,
Generic Oncology Drugs Market to 2027
The generic oncology drug market is expected to reach US $ 36,029.60 million in 2027, compared to US $ 21,200.00 in 2018. The market is expected to grow with a CAGR of 6.3% from 2019 to 2027.
Key factors such as increasing prevalence of cancer globally, increasing generic drug launches, and the benefits offered by generic drugs are likely to drive the market growth, while the inclination towards personalized cancer medicine is growing. likely to be a prevalent trend in future years. The generic oncology drugs market in Asia-Pacific is expected to grow at the highest rate during the forecast period. The growth is due to key factors such as large scale generic development, increased exports from Indian manufacturers, new trade agreements of Asian companies with international players for sale, distribution as well as research collaborations as well. as the launch of innovative and innovative products. generics for the treatment of cancer. The generic oncology drugs market in the Asia-Pacific region is expected to reach US $ 7,692.32 million in 2027, compared to US $ 4,299.63 million in 2018. The market growth rate in the region is estimated at 6 , 9% over the forecast period.
Download a sample report copy @ https://bit.ly/3wuVIF6
Best market players
Some of the major players operating in the generic oncology drug market are Teva Pharmaceutical Industries Ltd., Sandoz International GMBH, Glenmark, Sun Pharmaceutical Industries Ltd, MSN Laboratories, Aurobindo Pharma, Intas Pharmaceuticals, Zydus Cadila, Mylan NV, Cipla Inc., Fresenius Kabi AG and Dr. Reddy’s Laboratories Ltd., among others.
The global generic oncology drug market, based on molecule type, has been segmented into small molecule and large molecule. In 2018, the small molecule segment held the largest 87.67% market share of the generic oncology drug market, by molecule type. The advantages of small molecules in terms of complexity and molecular size which can span the entire scope to the target site and show its effective action as well as the advent of personalized drug development are the main factors that may explain the growth of the drug. segment over the years. come. However, the same segment is expected to experience the highest CAGR of 6.6% over the next few years.
Cancer is one of the leading causes of death worldwide and dramatically affects the quality of life. Thus, cancer will be a burden on society if it is not diagnosed and treated in time. According to the World Health Organization in 2018, around 9.6 million deaths worldwide were due to cancer. Additionally, the National Cancer Institute has predicted that in 2018, approximately 1,735,350 new cases of cancer will be diagnosed in the United States. In addition, the Asia-Pacific region is also facing the problem of increasing prevalence of cancer. The 15 countries most affected by cancer are: Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, ‘India, Laos and Cambodia. According to the National Institute for Cancer Prevention and Research (NICPR), in 2018 in India the total number of cancer deaths was 784,821. These statistics determine an increase in demand for advanced cancer diagnostics in India. various regions of the world. Thus stimulating the growth of generic drugs in oncology during the forecast period.
GLOBAL GENERIC ONCOLOGY DRUG MARKET –
Global Generic Oncology Drugs Market – By Molecule Type
• Large molecule
• Small molecule
Global Generic Oncology Drugs Market – By Application
• Lung cancer
• Stomach cancer
• Colorectal cancer
• Breast cancer
• Prostate cancer
• Liver cancer
• Kidney cancer
• Cervical cancer
Global Generic Oncology Drugs Market – By Region
• North America
• Asia-Pacific (APAC)
• South Korea
• Middle East and Africa (MEA)
• Saudi Arabia
• South Africa
• United Arab Emirates
• South America (SAM)
Purchase a full copy of this report @ https://bit.ly/3gnsQsq
Call: + 1-646-491-9876
Email: [email protected]
The Insight Partners is a one-stop-shop for industrial research in actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in technology, healthcare, manufacturing, automotive, and defense.
This version was posted on openPR.